Replies to post #184453 on Biotech Values

[DewDiligence]

MRK-CBST CC slides:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUxNzcwNTB8Q2hpbGRJRD01NjMwOTQ=

[GrthzGd]

Is MRK's Cubist acqusition grounds to update the $25M of value to which you ascribed ENTA's biocyclolide antibiotic in your analysis at 94993406?

[DewDiligence]

This puts a dent in the MRK-CBST deal:

http://in.reuters.com/article/2014/12/08/us-health-cubist-pharm-idINKBN0JM2HQ20141208

Hospira Inc can launch a generic version of Cubist Pharmaceuticals Inc 's leading drug Cubicin as soon as 2016, a federal judge has ruled.

U.S. District Judge Gregory Sleet in Delaware ruled Monday that four of Cubist's patents on Cubicin, an antibiotic injection used in hospitals to treat bacterial skin infections, were invalid.

Those patents would have given Cubist the exclusive right to sell Cubicin through November 2020. Sleet upheld one patent that expires in June 2016.

[DewDiligence]

MRK—(borrowing a page from VRX)—axes 120 CBST jobs:

http://www.fiercebiotech.com/story/merck-dumps-120-cubist-researchers-after-its-95b-merger/2015-03-05

[DewDiligence]

CAFC invalidates four of MRK’s Cubicin patents:

http://finance.yahoo.com/news/u-appeals-court-invalidates-four-180330943.html

Thursday's decision will keep a Cubicin generic out of the market only until June 2016. The court invalidated four of Merck's patents that would have protected the drug's market share up to 2020.

MRK says it may appeal to the USSC, If the CAFC’s ruling stands, it will lend credence to the notion that the $9.5B price MRK paid for CBST one year ago was too high (#msg-108853418).